Rabies vaccine (human diploid cell) for human use, Freeze-dried
Rabies vaccine (human diploid cell) for human use, Freeze-dried
Rabies vaccine (human diploid cell) for human use, Freeze-dried

Rabies vaccine (human diploid cell) for human use, Freeze-dried

Rabies vaccine (human diploid cell) for human use, Freeze-dried
Rabies vaccine (human diploid cell) for human use, Freeze-dried
Rabies vaccine (human diploid cell) for human use, Freeze-dried

Rabies vaccine (human diploid cell) for human use,  Freeze-dried

Drug Registration Approval in China, September 2023.

Second full vaccine production technology introduction project in China.
Support from the Science and Technology Commission of Beijing Municipal Government. 

 

【Active constituent】

 Sterile powder for injection, supplied with 1.0 ml of sterile water for injection sealed in a prefilled syringe.

【Strengths】

After reconstitution, each vial is 1.0ml. The rabies vaccine titer should not be less than 2.5IU per vial.

【Eligibles】

Persons bitten or scratched by dogs or other mad animals, regardless of age and sex. The vaccine should be administered to persons at risk of being exposed to rabies virus, such as veterinarians, animal keepers, forestry practitioners, slaughterhouse workers, and rabies laboratory personnel, according to the pre-exposure immunization program.

【Shelf Life】